Quest Diagnostics Inc Revenue
Quest Diagnostics Inc (DGX) reported Revenue of $3.04 billion for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-07-23
- Quest Diagnostics Inc revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $3.04B, a 10.21% increase year-over-year.
- Quest Diagnostics Inc revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $2.90B, a 9.16% increase year-over-year.
- Quest Diagnostics Inc revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $2.81B, a 7.06% increase year-over-year.
- Quest Diagnostics Inc revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $2.82B, a 13.18% increase year-over-year.
- Quest Diagnostics Inc revenue from contract with customer, excluding assessed tax for fiscal 2025 was $11.04B, a 11.78% increase from fiscal 2024.
- Quest Diagnostics Inc revenue from contract with customer, excluding assessed tax for fiscal 2024 was $9.87B, a 6.70% increase from fiscal 2023.
- Quest Diagnostics Inc revenue from contract with customer, excluding assessed tax for fiscal 2023 was $9.25B, a 6.38% decline from fiscal 2022.
- Quest Diagnostics Inc revenue from contract with customer, excluding assessed tax for fiscal 2022 was $9.88B, a 8.39% decline from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.04B 10-Q · filed 2026-07-23 | $5.94B 10-Q · filed 2026-07-23 | $8.74B derived: sum of 3 quarters · filed 2026-07-23 | $11.56B derived: sum of 4 quarters · filed 2026-07-23 |
| 2026-03-31 | $2.90B 10-Q · filed 2026-04-22 | $5.70B derived: sum of 2 quarters · filed 2026-04-22 | $8.52B derived: sum of 3 quarters · filed 2026-04-22 | $11.28B derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-12-31 | $2.81B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.62B derived: sum of 2 quarters · filed 2026-02-26 | $8.38B derived: sum of 3 quarters · filed 2026-07-23 | $11.04B 10-K · filed 2026-02-26 |
| 2025-09-30 | $2.82B 10-Q · filed 2025-10-21 | $5.58B derived: sum of 2 quarters · filed 2026-07-23 | $8.23B 10-Q · filed 2025-10-21 | $10.85B derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-06-30 | $2.76B 10-Q · filed 2026-07-23 | $5.41B 10-Q · filed 2026-07-23 | $8.03B derived: sum of 3 quarters · filed 2026-07-23 | $10.52B derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-03-31 | $2.65B 10-Q · filed 2026-04-22 | $5.27B derived: sum of 2 quarters · filed 2026-04-22 | $7.76B derived: sum of 3 quarters · filed 2026-04-22 | $10.16B derived: sum of 4 quarters · filed 2026-04-22 |
| 2024-12-31 | $2.62B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.11B derived: sum of 2 quarters · filed 2026-02-26 | $7.51B derived: sum of 3 quarters · filed 2026-02-26 | $9.87B 10-K · filed 2026-02-26 |
| 2024-09-30 | $2.49B 10-Q · filed 2025-10-21 | $4.88B derived: sum of 2 quarters · filed 2025-10-21 | $7.25B 10-Q · filed 2025-10-21 | $9.54B derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $2.40B 10-Q · filed 2025-07-23 | $4.76B 10-Q · filed 2025-07-23 | $7.05B derived: sum of 3 quarters · filed 2026-02-26 | $9.35B derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $2.37B 10-Q · filed 2025-04-23 | $4.65B derived: sum of 2 quarters · filed 2026-02-26 | $6.95B derived: sum of 3 quarters · filed 2026-02-26 | $9.29B derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $2.29B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.58B derived: sum of 2 quarters · filed 2026-02-26 | $6.92B derived: sum of 3 quarters · filed 2026-02-26 | $9.25B 10-K · filed 2026-02-26 |
| 2023-09-30 | $2.29B 10-Q · filed 2024-10-23 | $4.63B derived: sum of 2 quarters · filed 2024-10-23 | $6.96B 10-Q · filed 2024-10-23 | $9.30B derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | $2.34B 10-Q · filed 2024-07-24 | $4.67B 10-Q · filed 2024-07-24 | $7.00B derived: sum of 3 quarters · filed 2025-02-20 | $9.49B derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | $2.33B 10-Q · filed 2024-04-24 | $4.66B derived: sum of 2 quarters · filed 2025-02-20 | $7.15B derived: sum of 3 quarters · filed 2025-02-20 | $9.60B derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | $2.33B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $4.82B derived: sum of 2 quarters · filed 2025-02-20 | $7.27B derived: sum of 3 quarters · filed 2025-02-20 | $9.88B 10-K · filed 2025-02-20 |
| 2022-09-30 | $2.49B 10-Q · filed 2023-10-25 | $4.94B derived: sum of 2 quarters · filed 2023-10-25 | $7.55B 10-Q · filed 2023-10-25 | $10.29B derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $2.45B 10-Q · filed 2023-07-27 | $5.06B 10-Q · filed 2023-07-27 | $7.81B derived: sum of 3 quarters · filed 2024-02-22 | $10.58B derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $2.61B 10-Q · filed 2023-04-28 | $5.36B derived: sum of 2 quarters · filed 2024-02-22 | $8.13B derived: sum of 3 quarters · filed 2024-02-22 | $10.68B derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $2.74B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $5.52B derived: sum of 2 quarters · filed 2024-02-22 | $8.07B derived: sum of 3 quarters · filed 2024-02-22 | $10.79B 10-K · filed 2024-02-22 |
| 2021-09-30 | $2.77B 10-Q · filed 2022-10-21 | $5.32B derived: sum of 2 quarters · filed 2022-10-21 | $8.04B 10-Q · filed 2022-10-21 | $11.05B derived: sum of 4 quarters · filed 2022-10-21 |
| 2021-06-30 | $2.55B 10-Q · filed 2022-07-22 | $5.27B 10-Q · filed 2022-07-22 | $8.27B derived: sum of 3 quarters · filed 2022-07-22 | $11.06B derived: sum of 4 quarters · filed 2022-07-22 |
| 2021-03-31 | $2.72B 10-Q · filed 2022-04-22 | $5.72B derived: sum of 2 quarters · filed 2022-04-22 | $8.51B derived: sum of 3 quarters · filed 2022-04-22 | $10.34B derived: sum of 4 quarters · filed 2022-04-22 |
| 2020-12-31 | $3.00B 10-K · filed 2021-02-22 | $5.79B derived: sum of 2 quarters · filed 2021-10-22 | $7.62B derived: sum of 3 quarters · filed 2021-10-22 | $9.44B 10-K · filed 2023-02-21 |
| 2020-09-30 | $2.79B 10-Q · filed 2021-10-22 | $4.61B derived: sum of 2 quarters · filed 2021-10-22 | $6.43B 10-Q · filed 2021-10-22 | $8.36B derived: sum of 4 quarters · filed 2021-10-22 |
| 2020-06-30 | $1.83B 10-Q · filed 2021-07-23 | $3.65B 10-Q · filed 2021-07-23 | $5.58B derived: sum of 3 quarters · filed 2021-07-23 | $7.53B derived: sum of 4 quarters · filed 2021-07-23 |
| 2020-03-31 | $1.82B 10-Q · filed 2021-04-23 | $3.75B derived: sum of 2 quarters · filed 2021-04-23 | $5.70B derived: sum of 3 quarters · filed 2021-04-23 | $7.66B derived: sum of 4 quarters · filed 2021-04-23 |
| 2019-12-31 | $1.93B 10-K · filed 2021-02-22 | $3.88B derived: sum of 2 quarters · filed 2021-02-22 | $5.83B derived: sum of 3 quarters · filed 2021-02-22 | $7.73B 10-K · filed 2022-02-28 |
| 2019-09-30 | $1.96B 10-K · filed 2021-02-22 | $3.91B derived: sum of 2 quarters · filed 2021-02-22 | $5.80B 10-Q · filed 2020-10-23 | $7.64B derived: sum of 4 quarters · filed 2021-02-22 |
| 2019-06-30 | $1.95B 10-K · filed 2021-02-22 | $3.84B 10-Q · filed 2020-07-24 | $5.68B derived: sum of 3 quarters · filed 2021-02-22 | $7.57B derived: sum of 4 quarters · filed 2021-02-22 |
| 2019-03-31 | $1.89B 10-K · filed 2021-02-22 | $3.73B derived: sum of 2 quarters · filed 2021-02-22 | $5.62B derived: sum of 3 quarters · filed 2021-02-22 | $7.54B derived: sum of 4 quarters · filed 2021-02-22 |
| 2018-12-31 | $1.84B 10-K · filed 2020-02-20 | $3.73B derived: sum of 2 quarters · filed 2020-02-20 | $5.65B derived: sum of 3 quarters · filed 2020-02-20 | $7.53B 10-K · filed 2021-02-22 |
| 2018-09-30 | $1.89B 10-K · filed 2020-02-20 | $3.81B derived: sum of 2 quarters · filed 2020-02-20 | $5.69B 10-Q · filed 2019-10-23 | |
| 2018-06-30 | $1.92B 10-K · filed 2020-02-20 | $3.80B 10-Q · filed 2019-07-24 | ||
| 2018-03-31 | $1.88B 10-K · filed 2020-02-20 | |||
| 2017-12-31 | $7.40B 10-K · filed 2020-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LABCORP HOLDINGS INC. (LH) | United States | $25.060B | 22.60 |
| Guardant Health, Inc. (GH) | United States | $23.675B | -12.65 |
| Caris Life Sciences, Inc. (CAI) | United States | $9.119B | 47.87 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |